Product Name:MMAF sodium
IUPAC Name:sodium (2S)-2-[(2R)-2-[(R)-[(2S)-1-[(3R,4S,5S)-4-[(2S)-N,3-dimethyl-2-[(2S)-3-methyl-2-(methylamino)butanamido]butanamido]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl](methoxy)methyl]propanamido]-3-phenylpropanoate
| Packing Unit | Available Stock | Price($) | Quantity |
|---|
| Product Overview |
MMAF (Monomethyl auristatin F) is a synthetic derivative of dolastatin 10, a natural product isolated from the sea hare Dolabella auricularia. |
| Synthesis Method |
MMAF is synthesized through a series of chemical reactions starting from dolastatin 10. The process involves the protection of the hydroxyl groups on the dolastatin 10 molecule, followed by the introduction of a methyl group at the N-terminus. The final step involves the removal of the protecting groups to yield MMAF. |
| Chemical Properties |
It is a potent cytotoxic agent that can be used to selectively kill cancer cells. It is also stable and can be easily conjugated to antibodies. |
| Synthesis and Application |
It is used in MMAF (sodium), which are designed to selectively target cancer cells. MMAF (sodium) are composed of an antibody that recognizes a specific antigen on cancer cells and a cytotoxic agent, such as MMAF, that kills the cancer cells. MMAF has been used in clinical trials for the treatment of various types of cancer, including breast cancer, lung cancer, and lymphoma. |
| Future Directions |
One area of research is the development of novel MMAF (sodium) that can target different types of cancer. Another area of research is the optimization of the dosing and scheduling of MMAF to enhance its efficacy and minimize toxicity. In addition, there is ongoing research on the use of MMAF in combination with other anti-cancer agents to enhance its anti-tumor effects. Finally, there is a need for further research on the mechanism of action of MMAF to better understand its cytotoxic effects on cancer cells. |
Search 
+86 21 5895 0110 
